Coultreon banks $125M to support testing of former Galapagos immune drug
Summary
Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating m...
Description
Backed by Novo Holdings, Regeneron’s venture arm and several others, the biotech believes an oral drug licensed from Galapagos might hold potential treating m...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source